When was Iambic Therapeutics founded?

Iambic Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Iambic Therapeutics located?

Iambic Therapeutics is headquartered in San Diego, United States. It is registered at Midlothian, Virginia.

How many employees does Iambic Therapeutics have?

As of Aug 31, 2026, the latest employee count at Iambic Therapeutics is 182.

Is Iambic Therapeutics a funded company?

Iambic Therapeutics is a funded company, having raised a total of $334M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 14, 2021.

How much is Iambic Therapeutics worth?

The latest valuation of Iambic Therapeutics is $***** as of Apr 01, 2026.

When was the latest funding round of Iambic Therapeutics?

Iambic Therapeutics' latest funding was a $***** Conventional Debt round on Aug 14, 2026, with participation from 0 investor.

Where does Iambic Therapeutics rank among its competitors?

Iambic Therapeutics ranks 193rd amongst 3509 active competitors, of which 1185 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Iambic Therapeutics?

Iambic Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Iambic Therapeutics secured the most recent funding round in August, 2026.

Iambic Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Iambic Therapeutics is a series C company based in San Diego (United States), founded in 2019 by Fred Manby. It operates as a Provider of AI-driven drug discovery platform for the treatment of cancer. Iambic Therapeutics has raised $334M in funding from investors like Coatue, Abingworth and Exor, with a current valuation of $*****. The company has 3509 active competitors, including 1185 funded and 793 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.

Website: www.iambic.ai/
Social
Email ID: *****@iambic.ai
Phone Number: +1 **********
Registered Address: Midlothian, Virginia

Key Metrics

Founded Year

2019

Location

San Diego, United States

Stage

Series C

Total Funding

$334M in 6 rounds

Latest Funding Round

Conventional Debt, Aug 14, 2026, $*****

Post Money Valuation

$***** as on Apr 01, 2026

Investors

Coatue & 27 more

Ranked

193^rd among 3509 active competitors

Employee Count

182 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 5998 more

View Iambic Therapeutics' full profile

Iambic Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
IAMBIC THERAPEUTICS, INC. CIN: 7654610 , United States, Active	Oct 14, 2019	-	-	-
ENTOS LLC CIN: 453069439 , United States, Active	Oct 13, 2019	-	4 (As on Dec 31, 2024)	-

Iambic Therapeutics has raised a total funding of $334M over 6 rounds. Its first funding round was on Jul 14, 2021. Iambic Therapeutics has 27 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Iambic Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 14, 2026	2500439	Conventional Debt	5864672	9716498	1941939	3584461
Apr 01, 2026	5623739	Series C	9048658	4798559	9230632	4072768
Nov 06, 2025	5732860	Series C	9459497	3839664	4817091	Abingworth & 16 more

Access funding benchmarks and valuations. Sign up today!

View details of Iambic Therapeutics's funding rounds and investors

The founders of Iambic Therapeutics is Fred Manby.

Here are the details of Iambic Therapeutics' key team members:

Fred Manby: Co-Founder & CTO of Iambic Therapeutics.
Contact Info: 1 email address

View details of Iambic Therapeutics's Founder profiles and Board Members

Iambic Therapeutics' employee count trend

Iambic Therapeutics has 182 employees as of Aug 26. Here is Iambic Therapeutics's employee count trend over the years:

Employee count trend for Iambic Therapeutics

Uncover Iambic Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Iambic Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Iambic Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
4th	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, DCVC & 47 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
193rd	Iambic Therapeutics 2019, San Diego (United States), Series C	Provider of AI-driven drug discovery platform for the treatment of cancer	$334M	Sequoia Capital, Pegasus Tech Ventures & 26 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Iambic Therapeutics's competitors? Click here to see the top ones

Iambic Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Iambic Therapeutics's sector:

Free

Oncology - Sector Report

Edition: July, 2026 (74 Pages)

View all reports related to Iambic Therapeutics

Media has covered Iambic Therapeutics for a total of 16 events in the last 1 year, 5 of them have been about partnerships and 3 about company updates.